
## A P S Hungin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10382845/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidenceâ€based international consensus. Alimentary Pharmacology and Therapeutics, 2018, 47, 1054-1070.	1.9	101
2	Prevalence, symptom patterns and management of episodic diarrhoea in the community: a populationâ€based survey in 11 countries. Alimentary Pharmacology and Therapeutics, 2016, 43, 586-595.	1.9	9
3	World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2016, 50, 704-713.	1.1	90
4	Irritable bowel syndrome: an integrated explanatory model for clinical practice. Neurogastroenterology and Motility, 2015, 27, 750-763.	1.6	22
5	Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care - A Rome Foundation Working Team Report. Alimentary Pharmacology and Therapeutics, 2014, 40, 1133-1145.	1.9	40
6	Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Alimentary Pharmacology and Therapeutics, 2013, 38, 864-886.	1.9	168
7	Symptoms in patients on longâ€ŧerm proton pump inhibitors: prevalence and predictors. Alimentary Pharmacology and Therapeutics, 2009, 29, 431-439.	1.9	28
8	Systematic review: frequency and reasons for consultation for gastroâ€oesophageal reflux disease and dyspepsia. Alimentary Pharmacology and Therapeutics, 2009, 30, 331-342.	1.9	60
9	<i>Helicobacter pylori</i> eradication in longâ€ŧerm proton pump inhibitor users is highly costâ€effective: economic analysis of the HELPUP trial. Alimentary Pharmacology and Therapeutics, 2008, 28, 1297-1303.	1.9	10
10	Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. Family Practice, 2008, 26, 40-47.	0.8	45
11	GPs' explanatory models for irritable bowel syndrome: a mismatch with patient models?. Family Practice, 2008, 26, 34-39.	0.8	33
12	Helicobacter pylori eradication in longâ€ŧerm proton pump inhibitor users in primary care: a randomized ontrolled trial. Alimentary Pharmacology and Therapeutics, 2007, 25, 585-592.	1.9	14
13	Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterology, 2007, 7, 20.	0.8	44
14	Self-help interventions in irritable bowel syndrome. Gut, 2006, 55, 603-604.	6.1	10
15	Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Alimentary Pharmacology and Therapeutics, 2005, 21, 1365-1375.	1.9	413
16	Review article: gastro-oesophageal reflux disease - the health economic implications. Alimentary Pharmacology and Therapeutics, 2005, 22, 20-31.	1.9	32
17	Review article: quality-of-life issues in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2005, 22, 41-47.	1.9	45
18	The Fight for â€~Health-related Normality': A Qualitative Study of the Experiences of Individuals Living with Established Inflammatory Bowel Disease (IBD). Journal of Health Psychology, 2005, 10, 443-455.	1.3	107

A P S HUNGIN

#	Article	IF	CITATIONS
19	Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners. Digestion, 2005, 72, 212-218.	1.2	20
20	The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Alimentary Pharmacology and Therapeutics, 2004, 20, 733-744.	1.9	68
21	Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Alimentary Pharmacology and Therapeutics, 2004, 19, 529-535.	1.9	77
22	The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Alimentary Pharmacology and Therapeutics, 2003, 17, 643-650.	1.9	654
23	Dyspepsia: gaps between primary and secondary care. Digestive and Liver Disease, 2002, 34, 243-245.	0.4	2
24	Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Alimentary Pharmacology and Therapeutics, 2002, 16, 167-180.	1.9	1,068
25	Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Alimentary Pharmacology and Therapeutics, 2002, 16, 1889-1893.	1.9	30
26	Inflammatory bowel disease: epidemiology and management in an English general practice population. Alimentary Pharmacology and Therapeutics, 2000, 14, 1553-1559.	1.9	252